Skip to content

EuropaBio Most Innovative EU Biotech SME Award top 5 candidates

The top five candidates to compete in this year’s EuropaBio Most Innovative EU Biotech SME Award have been selected. Entering its 4th year, the award has grown rapidly each year.

This year, the award will be presented during the first ever European Biotechnology Week, at an event in Brussels. 

The candidates are:

EryDel SpA, an Italian innovative drug delivery company, specialised in the development of drugs and diagnostics delivered through human red blood cells

E-Therapeutics, a UK biotech SME, has pioneered ‘network pharmacology,’ a new approach to drug discovery based on advances in network science and chemical biology, with which it seeks novel treatments for complex diseases, principally cancer and disorders of the nervous system.

Gensight biologics from France are dedicated to the development of gene therapy based treatments for degenerative retinal diseases.

Nanobiotix, also hailing from France, aims to enhance the efficacy of radiotherapy treatment in meeting the needs of cancer patients by developing innovative technology that uses nanoparticles called nanoXray, designed to directly enter tumour cells through either direct injection, intravenous injection, or topical application.

UK based PsiOxus Therapeutics is developing a new approach to cancer therapy by using the processes of directed evolution to develop a virus that is a potent killer of cancer cells but with minimal effects on normal healthy cells.